iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
ICAD Stock | USD 1.79 0.02 1.10% |
About 62% of Icad's investor base is looking to short. The analysis of the overall investor sentiment regarding icad inc suggests that many traders are alarmed. The current market sentiment, together with Icad's historical and current headlines, can help investors time the market. In addition, many technical investors use icad inc stock news signals to limit their universe of possible portfolio assets.
Icad |
Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite ExpansionNASHUA, N.H. and WILLIAMSVILLE, N.Y. and RALEIGH, N.C., July 29, 2024 -- iCAD, Inc. a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategic agreement with Windsong Radiology Group, one of US Radiology Specialists, Inc.s national network of premier providers of diagnostic imaging services located in Western New York. This relationsh
Read at finance.yahoo.com
Icad Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Icad can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Icad Fundamental Analysis
We analyze Icad's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Icad using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Icad based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Icad is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
icad inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Icad stock to make a market-neutral strategy. Peer analysis of Icad could also be used in its relative valuation, which is a method of valuing Icad by comparing valuation metrics with similar companies.
Peers
Icad Related Equities
LNSR | LENSAR | 7.49 | ||||
BMRA | Biomerica | 3.23 | ||||
AIMD | Ainos | 2.33 | ||||
AXGN | Axogen | 1.86 | ||||
SSKN | STRATA Skin | 1.67 | ||||
SGHT | Sight Sciences | 1.12 | ||||
SIBN | Si Bone | 0.51 | ||||
SRDX | SurModics | 0.17 | ||||
CVRX | CVRx | 1.64 | ||||
PROF | Profound Medical | 2.16 | ||||
NVRO | Nevro Corp | 2.41 | ||||
NVNO | EnVVeno Medical | 2.45 | ||||
ESTA | Establishment Labs | 2.49 | ||||
FNA | Paragon 28 | 3.54 | ||||
MOVE | Movano | 6.81 |
Complementary Tools for Icad Stock analysis
When running Icad's price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |